AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00022334 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFP
Description: Increasing doses of AFP will be given to groups of 3 intradermally. Subjects will receive 3 biweekly vaccinations. At least 2 patients at a given dose must have received their complete 3 vaccination schedule with a 30 day observation period after the last vaccination before a higher dose is initiated.
Study NCT00385008 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Combination Product (sumatriptan succinate / naproxen sodium)
Description: sumatriptan/naproxen sodium
Study NCT00385008 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: RELPAX(eletriptan) 40mg Tablet
Description: eletriptan tablets
Study NCT00616070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate
Description: Difluprednate
Study NCT00616070 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle
Study NCT01285297 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate Concentrate
Description: Injection of up to 18 mL BMAC
Study NCT01936506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training A
Study NCT01936506 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training B
Study NCT02304497 — intervention group
Intervention type: OTHER
Intervention: Platelet Rich Fibrin
Description: Procedure: Platelet Rich Fibrin obtained
Study NCT02310256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Five plus exercise training
Description: calf raise exercise
Study NCT01799044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Tumor ablation with irreversible electroporation with the NanoKnife
Study NCT02732171 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Research Blood Collection
Description: Multiple tubes of research blood collected for biomarker analyses (circulating tumor material, immune profiling)
Study NCT00934687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clostridium botulinum toxin type A neurotoxin complex
Description: A total of 20-50 U of clostridium botulinum toxin type A neurotoxin complex (Allergan) will be injected at four to six sites in the glabella region according to standard protocols of cosmetic botulinum toxin applications.
Study NCT00934687 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl solution
Description: 0.9% NaCl solution will be injected in analogy to clostridium botulinum toxin type A neurotoxin complex as a placebo comparator.
Study NCT02404376 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Remote Ischemic Conditioning (RIC)
Description: Remote ischemic conditioning with a cuff in the arm
Study NCT02404376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intrevenous administration of Placebo
Study NCT02404376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Intrevenous administration of Placebo
Study NCT02418988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Trans-catheter chemo-embolization (TACE) without rAd-p53 injection will be given every 21 days
Study NCT03024645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be A Mom
Description: The Be a Mom program is a web-based self-guided cognitive-behavioral intervention to prevent postpartum depression, targeting postpartum women. It consists of 5 weekly modules, each module targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
Study NCT02255721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHIP (Sleep Health in Preschoolers)
Description: SHIP (Sleep Health in Preschoolers) is a family-centered health behavior change intervention for child behavioral sleep problems delivered 1:1 to parents via a home visit and follow-up phone calls.
Study NCT02255721 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SHIP Control Arm
Description: Families will receive a family-centered health behavior change intervention for child health topics unrelated to sleep or outcome measures, delivered 1:1 to parents via a home visit and follow-up phone calls.
Study NCT03024645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usually (TAU)
Description: performed in primary care settings
Study NCT03024645 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usually (TAU)
Description: performed in primary care settings
Study NCT01944579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blackberries
Description: Participants will receive blackberries as part of a controlled diet.
Study NCT01944579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants will receive a control food (jello) as part of a controlled diet.
Study NCT00316888 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT00316888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00316888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT01693510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Nutrition Intervention
Description: Both Intervention and Control participants and their care providers receive the new Health Canada guide on Healthy Weight Gain During Pregnancy. For the Experimental Group, the exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program to reach 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling.
Study NCT01867203 — intervention group
Intervention type: OTHER
Intervention: Genotyping
Description: DNA extraction from blood
Study NCT01228578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin supplements B,C and E
Description: One daily recommended dietary allowance of multivitamins B,C and E or placebo taken daily for 18 months
Study NCT01228578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Multivitamin supplements B,C and E
Description: One daily recommended dietary allowance of multivitamins B,C and E or placebo taken daily for 18 months
Study NCT02487303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen Intravenous
Description: IV 1 gram f3 doses over 24 hours
Study NCT02487303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen Oral
Description: Oral 1 gram 3 doses over 24 hours
Study NCT00316888 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Given once daily 5 days a week for 5 weeks
Study NCT00584571 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sensory Adaptation Training
Description: This study will last for approximately 3 months and will include 4-6 clinic visits with each visit lasting 2 hours every week or every 2 weeks. At the beginning of each visit we will ask you about your health status and level of satisfaction of your bowel habits. We will then place the pencil-thick probe and balloon inside your rectum and attach it to the barostat device and a computer. We will increase and decrease the volumes of the balloon until the most pressure you can tolerate or a certain level of pressure as measured by the machine is reached, whichever occurs first. You will continue to keep stool diaries and pain diaries for 7 days before and after each visit.
Study NCT00584571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram Therapy
Description: Escitalopram; 10 mg every day, orally.
Study NCT01837667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB-100 for Injection
Description: Part 1 and Part 2: LB-100 for Injection infusion on Days 1,2,3 of each 21 day cycle.
Study NCT01837667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Part 2: Docetaxel infusion on Day 2 of each 21 day cycle.
Study NCT04059679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 Mg Oral Tablet
Description: EC aspirin (81mg qd) plus rivaroxaban (2.5 mg bid)
Study NCT04059679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81 mg
Description: EC aspirin 81 mg qd
Study NCT04059679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: EC aspirin 81 mg qd
Study NCT00614315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLAIR™ Endovascular Stent Graft
Description: The FLAIR™ Endovascular Stent Graft is designed to treat venous anastomotic stenoses of AV access grafts, providing both structural support of the site following angioplasty (stent), and a barrier to locally recurrent flow-limiting neointimal tissue growth (covering/graft).
Study NCT00651326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buserelin
Study NCT03007992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Oral vinorelbine will be administered at a daily dose of 30 mg (flat dose without any adaptation to body weight or body surface area) without breaks. Treatment will continue until disease progression, occurrence of unacceptable toxicity, patient's refusal or investigator's decision to stop the treatment.
Study NCT01106014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Selexipag 200 µg tablets
Study NCT01669915 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day
Study NCT01669915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
Study NCT01669915 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D placebo
Study NCT01669915 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D placebo
Study NCT01669915 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo
Study NCT01669915 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo
Study NCT04263207 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT01710956 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Arm 1: with twice-daily thoracic radiotherapy/ Arm 2: with once-daily thoracic radiotherapy
Description: Arm 1: with twice-daily thoracic radiotherapy daily 1.5gy/fr. bid, total 45gy(30fr during 3weeks) Arm 2: with once-daily thoracic radiotherapy daily 2.4gy/fr. qd, total 60gy(25fr during 5weeks)
Study NCT02533947 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention consists of an individually tailored supervised exercise program with aerobic, strength and coordinative components.
Study NCT02533947 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: A waitlist control group will get the intervention after 7 month of treatment as usual.
Study NCT03904433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coconut oil
Description: Coconut oil given in coffee with cream
Study NCT03904433 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caprylic acid
Description: Caprylic acid given in coffee with cream
Study NCT01106014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching selexipag
Study NCT03904433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunflower oil
Description: Sunflower oil given in coffee with cream
Study NCT03904433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose dissolved in water
Study NCT02370979 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Study NCT04247581 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 1-lead ECG
Description: 1 lead ECG - All participants will record three single-lead ECGs at rest and three single-lead ECGs after exercise.~Intervention Other: Exercise - All participants will undergo three trials of exercise.~Other interventions: 12-lead ECG - All participants will simultaneously record 12-lead ECGs during rest and exercise sessions.
Study NCT02710045 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles Vaccine at 9 months of age
Description: Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 9 months of age
Study NCT02710045 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTP Vaccine at 9 months of age
Description: Single intramuscular (i.m.) dose of diphtheria-tetanus-whole cell pertussis vaccine (Serum Institute of India Ltd.) into the thigh at 9 months of age
Study NCT02710045 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles Vaccine at 18 months of age
Description: Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 18 months of age
Study NCT02166554 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: On the day of initial surgery
Study NCT02166554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cross-linked Hyaluronan Hydrogel
Description: On the day of the initial surgery
Study NCT00686842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEGF inhibitor PTC299
Description: 20 mg capsules to be taken by mouth BID. Three dose levels will be evaluated: 40 mg, 80mg, and 100mg BID. Subjects will receive PTC299 in consecutive 28-day cycles for a maximum of 12 cycles.
Study NCT01291758 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Submaximal bicycle exercise stress tests performed 24 hr apart
Description: Submaximal bicycle exercise stress tests were performed for 25 min at 70% predicted heart rate, then ramped up to 85% predicted heart rate. Subjects could stop when they felt they had reached their maximum effort if before reaching 85% predicted heart rate.
Study NCT00686842 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
Study NCT03620045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute moderate physical activity
Description: For 20 minutes, participants will walk on a treadmill at a moderate intensity based on a combination of evidence-based and pre-determined parameters, including ratings of perceived exertion and heart rate
Study NCT01670591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PS - Prevention in School
Study NCT00686842 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
Study NCT04382573 — intervention group
Intervention type: GENETIC
Intervention: Epigenetic signatures
Description: Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
Study NCT05938933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PHP
Description: personalized health planning (PHP)
Study NCT05938933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMA
Description: shared medical appointments (SMAs)
Study NCT01747941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06305591
Description: single dose, solution
Study NCT01747941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo
Study NCT00651326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flutamide
Study NCT00686842 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
Study NCT00686842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
Study NCT00686842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
Study NCT00686842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: To describe the pharmacokinetics of PTC299 in patients with HIV-associated KS. To describe the effects of PTC299 on circulating VEGF, VEGFR and cytokine levels in patients with HIV-associated KS.
Study NCT00686842 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
Study NCT01430676 — intervention group
Intervention type: PROCEDURE
Intervention: differences in surgical techniques
Description: follow the risk for morbidity after incisional hernia repair
Study NCT03278431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Albendazole (400 mg) from Janssen, donated by the World Health Organization
Study NCT03278431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Albendazole (400 mg) from Janssen, donated by the World Health Organization
Study NCT03278431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrantel Pamoate
Description: Pyrantel pamoate (20 mg/kg), will be purchased by the World Health Organization
Study NCT03278431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrantel Pamoate
Description: Pyrantel pamoate (20 mg/kg), will be purchased by the World Health Organization
Study NCT03278431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxantel Pamoate
Description: Oxantel pamoate (20mg/kg) will be produced by the University of Basel
Study NCT03278431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxantel Pamoate
Description: Oxantel pamoate (20mg/kg) will be produced by the University of Basel
Study NCT03278431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: Mebendazole (500 mg) from GlaxoSmithKline, donated by the World Health Organization
Study NCT04149574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified Dose on Specified Days
Study NCT04149574 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified Dose on Specified Days
Study NCT04149574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG)
Description: Specified Dose on Specified Days
Study NCT04149574 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Bacillus Calmette-Guérin (BCG)
Description: Specified Dose on Specified Days
Study NCT01983280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healing Touch
Study NCT03432416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NES-E2 CVR
Description: NES-E2 CVR
Study NCT04342689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dietary Supplement containing resistant starch
Description: Two tablespoons (\~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14)
Study NCT04342689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Starch
Description: Two tablespoons (\~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14)
Study NCT00205543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uvulopalatopharyngoplasty with or without sutures
Description: standard UPPP
Study NCT00573807 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Far Infrared Radiation (5μm to 20μm wavelength)
Description: Far Infrared Radiation (5μm to 20μm wavelength)for 30 to 40 minutes per treatment session.